Toshizo Takayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Toshizo Takayama has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
A. Nakata
1 shared publicationA. Sugaya
1 shared publication- F. Hanamura1 shared publication
H. Sagara
1 shared publication- Hiroyuki Kodama
Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan
1 shared publication K. Shiraishi
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 14
Real-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study
- 22 September 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 14
Open AccessReal-world efficacy, safety, and treatment continuity of fruquintinib in Japanese patients with colorectal cancer: a multicentre retrospective study
- Open Access
- 24 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6727
Updated Adjuvant Chemotherapy for Gastric Cancer
Surgical resection is currently the best curative approach for gastric cancer (GC); however, the prognosis of patients with advanced GC remains poor even with curative resection. For this reason, perioperative chemotherapy has been combined with surgery to reduce the risk of postoperative recurrence. Standard perioperative chemotherapy for resectable advanced GC varies from region to region. Postoperative S-1 therapy was standardized via the ACTS-GC study in East Asia, perioperative ECF (Epirubicin + Cisplatin + Fluorouracil) was standardized via the MAGIC study in Europe, and postoperative chemoradiotherapy was standardized via the US intergroup study in North America. Since then, more intensive regimens have been developed. In recent years, perioperative therapy using novel agents, such as molecular-targeted drugs and immune checkpoint inhibitors (ICIs), has also been tested and evaluated in the three major regions (East Asia, Europe, and North America) with promising results. Perioperative chemotherapy has become an integral part of many treatment strategies and requires continued research and evaluation.
- 24 October 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (21) , 6727
Open AccessUpdated Adjuvant Chemotherapy for Gastric Cancer
Surgical resection is currently the best curative approach for gastric cancer (GC); however, the prognosis of patients with advanced GC remains poor even with curative resection. For this reason, perioperative chemotherapy has been combined with surgery to reduce the risk of postoperative recurrence. Standard perioperative chemotherapy for resectable advanced GC varies from region to region. Postoperative S-1 therapy was standardized via the ACTS-GC study in East Asia, perioperative ECF (Epirubicin + Cisplatin + Fluorouracil) was standardized via the MAGIC study in Europe, and postoperative chemoradiotherapy was standardized via the US intergroup study in North America. Since then, more intensive regimens have been developed. In recent years, perioperative therapy using novel agents, such as molecular-targeted drugs and immune checkpoint inhibitors (ICIs), has also been tested and evaluated in the three major regions (East Asia, Europe, and North America) with promising results. Perioperative chemotherapy has become an integral part of many treatment strategies and requires continued research and evaluation.